<DOC>
	<DOCNO>NCT02275299</DOCNO>
	<brief_summary>This study intend evaluate efficacy safety Iguratimod Plus Methotrexate Compared Leflunomid Plus Methotrexate patient active Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>Study Iguratimod Plus Methotrexate Compared Leflunomid Plus Methotrexate Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>Subjects diagnosis RA accord diagnostic criterion American College Rheumatology ( ACR ) ( revised 1987 ) Rheumatoid Arthritis 3 month time initial diagnosis Functional Class IIIII Subjects active RA time screen Subjects inadequate response biologics washout period initiation study . For etanercept , washout period 2week , 8week infliximab adalimumab . For firstly diagnostic RA patient , disease activity moderate severe , DAS28 &gt; 3.2 Must least 4 tender joint ( 66 join count ) 8 swollen joint ( 68 join count ) screen baseline Has Creactive protein ≥ 10 mg/L ( 1.0 mg/dL ) OR Erythrocyte Sedimentation Rate ( ESR ) ≥ 28 mm/hr Must negative Pregnancy test use adequate method contraception throughout trial Written inform consent Preceding treatment DMARDs , immunosuppressant ( cyclophosphamide , cyclosporine , azathioprine , etc . ) , Tripterygium within 4 week prior study entry Subjects treat iguratimod leflunomide combine MTX screen . Subjects combine autoimmune disease , systemic lupus erythematosus ( SLE ) , mixed connective tissue disease ( MCTD ) , scleriasis polymyositis , except Sjögren syndrome . Chest xray abnormality , tuberculosis , interstitial pulmonary fibrosis , etc . ALT &gt; 1.5×ULN , AST &gt; 1.5×ULN , Cr &gt; 135umol/L , total bilirubin &gt; 1.5×ULN WBC &lt; 4×109/L，HGB &lt; 85g/L，PLT &lt; 100×109/L Subjects serious cardiovascular , renal , hematologic , endocrine disease malignant Women Pregnant breastfeeding , male female recent plan conception Subjects immunodeficiency , uncontrolled infection active gastrointestinal disease Allergic study drug History alcoholism Subjects mental illness Subjects receive live vaccine recently Subjects participate clinical study within 3 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>